Human Infection Studies and the SARS-CoV-2 Pandemic
Abstract
Introduction-What could humanity have done better in fighting the SARS-CoV-2 pandemic? From a financial and scientific point of view, it has done many things right, but a crucial ethical question has remained rather unexamined. In this paper, I argue that controlled human infection studies (HIS) would have been ethically justifiable and the right way forward in developing a vaccine against Covid-19. The phase 2/3 trials of the vaccines from AstraZeneca, Pfizer/Biontech and Moderna took between 112 and 196 days. Human challenge trials would have taken much less time, about 30 days. In retrospect, these three vaccines could have been launched 82 to 166 days earlier than they actually were. If this had happened, hundreds of thousands of deaths and millions of hospitalisations worldwide could have been avoided due to the cumulative effect. In terms of preparatory measures for the next pandemic, the ethical discussion on HIS is of utmost relevance for the well-being of future generations.
Downloads
How to Cite
References
Lindsey Baden, Hana El Sahly (2021) Efficacy and Safety of the mRNA-1273 30 Kremsner et al. 2021a. SARS-CoV-2 Vaccine. 384(5), 403-416.
N Eyal, M Lipsitch, P Smith (2020) Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure. XX, 1-5.
Laura Gallagher (2021) call-for-investigation-of-rodneys-death-feb-17-1987-1-p.
Tuvan Gumrukcu, Ali Kucukgocmen (2020) Turkey says China's Sinovac COVID vaccine 91.25% effective in late trials.
Euzebiusz Jamrozik, Michael Selgelid (2021) Human Challenge Studies in Endemic Settings.
Peter Kremsner, Philipp Mann, Arne Kroidl, Isabel Leroux-Roels, Christoph Schindler, Julian Gabor, Mirjam Schunk, Geert Leroux-Roels, Jacobus Bosch, Rolf Fendel, Andrea Kreidenweiss, Thirumalaisamy Velavan, Mariola Fotin-Mleczek, Stefan Mueller, Gianluca Quintini, Oliver Schönborn‑kellenberger, Dominik Vahrenhorst, Thomas Verstraeten, Margarida Alves De Mesquita, Lisa Walz, Olaf‑oliver Wolz, Lidia Oostvogels, Fien De Boever, Anniek Desimpel, Meral Esen, Ina Fischer, Judith Flügge, Otto Geisenberger, Christof Geldmacher, Katrin Held, Larissa Hoffmann, Michael Hölscher, Kristina Huber, Bart Jacobs, Jasper Joye, Jacqueline Kirschke, Norman Klopp, Erik Koehne, Carsten Köhler, Albert Lalremruata, Carlos Lamsfus-Calle, Le Linh, Cathy Maes, Dafni Metaxa, Marie-Luise Molnar, Mariana Mueller, Gesine Müller-Schöner, Marion Quindel, Sabine Rappe, Liz Schultze-Naumburg, Carsten Schumacher, Sabine Schuster, Verena Thiel, Susanne Vejda, Gwenn Waerlop, Carola Westenberg, Katrin Wons, Andreas Zeder (2021) Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2. 133(17-18), 931-941.
Kremsner Peter, G Guerrero, Rodolfo Arana-Arri, Eunate (2021) Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial. 22, 329-340.
Fernando Polack, Stephen Thomas, Nicholas Kitchin, Judith Absalon, Alejandra Gurtman, Stephen Lockhart, John Perez, Gonzalo Pérez Marc, Edson Moreira, Cristiano Zerbini, Ruth Bailey, Kena Swanson, Satrajit Roychoudhury, Kenneth Koury, Ping Li, Warren Kalina, David Cooper, Robert Frenck, Laura Hammitt, Özlem Türeci, Haylene Nell, Axel Schaefer, Serhat Ünal, Dina Tresnan, Susan Mather, Philip Dormitzer, Uğur Şahin, Kathrin Jansen, William Gruber (2020) Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. 383(27), 2603-2615.
Stephan Reich (2021) http://ljournal.ru/wp-content/uploads/2016/08/d-2016-154.pdf.
Seema Shah (2020) Ethics of controlled human infection to address COVID-19. 368(6493), 832-834.
Jörg Tremmel (2021) Unknown Title.
(2007) FDA Issues Guidance for Collection of Race and Ethnicity Data in Clinical Trials for FDA Regulated Products.
Merryn / Voysey, Suea Clemens, Shabir Madhi (2021) Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. 397, 99-111.
Haidong Wang (2022) Australian COVID-19 pandemic: A Bradford Hill Analysis of Iatrogenic Excess Mortality. 8(2).
(2020) Key criteria for the ethical acceptability of Covid-19 human challenge studies.
Published
2023-03-27
Issue
Section
License
Copyright (c) 2023 Authors and Global Journals Private Limited
This work is licensed under a Creative Commons Attribution 4.0 International License.